207 related articles for article (PubMed ID: 10073378)
1. Cost of treating mental illness from a managed care perspective.
Docherty JP
J Clin Psychiatry; 1999; 60 Suppl 3():49-52; discussion 53. PubMed ID: 10073378
[TBL] [Abstract][Full Text] [Related]
2. Methods of cost-effectiveness analysis in the evaluation of new antipsychotics: implications for schizophrenia treatment.
Neumann PJ
J Clin Psychiatry; 1999; 60 Suppl 3():9-14; discussion 15. PubMed ID: 10073371
[TBL] [Abstract][Full Text] [Related]
3. Managed care, networks and trends in hospital care for mental health and substance abuse treatment in Massachusetts: 1994-1999.
Fleming E; Lien H; Ma CT; McGuire TG
J Ment Health Policy Econ; 2003 Mar; 6(1):3-12. PubMed ID: 14578543
[TBL] [Abstract][Full Text] [Related]
4. Medicaid managed care and the distribution of societal costs for persons with severe mental illness.
Shern DL; Jones K; Chen HJ; Jordan N; Ramoni-Perazzi J; Boothroyd RA
Am J Psychiatry; 2008 Feb; 165(2):254-60. PubMed ID: 18198269
[TBL] [Abstract][Full Text] [Related]
5. The impact of managed behavorial healthcare on the costs of psychiatric and chemical dependency treatment.
Geraty R; Bartlett J; Hill E; Lee F; Shusterman A; Waxman A
Behav Healthc Tomorrow; 1994; 3(2):18-30. PubMed ID: 10172255
[TBL] [Abstract][Full Text] [Related]
6. Dialogue. Prescription for problems? Capitating mental health drugs--the great debate.
Docherty JP; Browne RA; Farmer M
Behav Healthc Tomorrow; 1998 Oct; 7(5):32-8. PubMed ID: 10185199
[TBL] [Abstract][Full Text] [Related]
7. Managed care's atypical response. New antipsychotics show promise, but are they getting into enough hands?
Waldron T
Behav Healthc Tomorrow; 1999 Apr; 8(2):28-31. PubMed ID: 10351297
[No Abstract] [Full Text] [Related]
8. Impact of formulary restrictions on the cost-effectiveness of antidepressant treatment.
Sheehan DV; Wright-Etter PJ
Manag Care Q; 2002; 10(3):21-31. PubMed ID: 12476662
[TBL] [Abstract][Full Text] [Related]
9. Improving mental health treatments through comparative effectiveness research.
Wang PS; Ulbricht CM; Schoenbaum M
Health Aff (Millwood); 2009; 28(3):783-91. PubMed ID: 19414887
[TBL] [Abstract][Full Text] [Related]
10. Perspective and the measurement of costs and benefits for cost-effectiveness analysis in schizophrenia.
Meltzer D
J Clin Psychiatry; 1999; 60 Suppl 3():32-5; discussion 36-7. PubMed ID: 10073375
[TBL] [Abstract][Full Text] [Related]
11. Opportunities for improving managed care for individuals with dementia: Part 1--The issues.
Fillit H; Knopman D; Cummings J; Appel F
Am J Manag Care; 1999 Mar; 5(3):309-15. PubMed ID: 10351027
[TBL] [Abstract][Full Text] [Related]
12. Atypical antipsychotics in the managed care era.
Loebel AD; Botts SR; Feldman BI
Am J Manag Care; 1998 Jan; 4 Suppl():S37-50; quiz S51-2. PubMed ID: 10181074
[TBL] [Abstract][Full Text] [Related]
13. Treatment of common mental disorders in primary care in low- and middle-income countries.
Siddiqi K; Siddiqi N
Trans R Soc Trop Med Hyg; 2007 Oct; 101(10):957-8. PubMed ID: 17540425
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of usual general practitioner care with or without antidepressant medication for patients with minor or mild-major depression.
Bosmans JE; Hermens ML; de Bruijne MC; van Hout HP; Terluin B; Bouter LM; Stalman WA; van Tulder MW
J Affect Disord; 2008 Nov; 111(1):106-12. PubMed ID: 18342952
[TBL] [Abstract][Full Text] [Related]
15. Economic analysis of oral and topical therapies for onychomycosis of the toenails and fingernails.
Casciano J; Amaya K; Doyle J; Arikian S; Shear N; Haspel M; Kahler K
Manag Care; 2003 Mar; 12(3):47-54. PubMed ID: 12685377
[TBL] [Abstract][Full Text] [Related]
16. Limiting access to psychiatric services can increase total health care costs.
Horn SD
J Clin Psychiatry; 2003; 64 Suppl 17():23-8. PubMed ID: 14680424
[TBL] [Abstract][Full Text] [Related]
17. Formulary decisions and health economics.
Glazer WM
J Clin Psychiatry; 1998; 59 Suppl 19():23-9. PubMed ID: 9847049
[TBL] [Abstract][Full Text] [Related]
18. The costs of depression: direct and indirect; treatment versus nontreatment.
Panzarino PJ
J Clin Psychiatry; 1998; 59 Suppl 20():11-4. PubMed ID: 9881536
[TBL] [Abstract][Full Text] [Related]
19. Annual health outcomes and treatment costs for schizophrenia populations.
Mauskopf JA; David K; Grainger DL; Gibson PJ
J Clin Psychiatry; 1999; 60 Suppl 19():14-9; discussion 20-2. PubMed ID: 10507276
[TBL] [Abstract][Full Text] [Related]
20. Pharmacoeconomics of schizophrenia in the 21st century.
Hanson MA
J Clin Psychiatry; 1999; 60 Suppl 1():26-7; discussion 28-30. PubMed ID: 10037168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
